COMP <GO>
RVMD vs AMGN // REVENUE GROWTH (YOY)
Revolution Medicines Inc. (NASDAQ) VS. Amgen Inc. (NASDAQ) • 15-METRIC TALLY: RVMD 3
— AMGN 7
▲ REVENUE GROWTH (YOY) LEADER: RVMD
LAST: $191.31 (+0.55%) • MKT CAP: $40.78B
revenue-growth
15.40%
LAST: $466.01 (+1.15%) • MKT CAP: $249.09B
revenue-growth
10.00%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (RVMD VS. AMGN)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | RVMD | AMGN | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | 67.20% | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -28.60% | 14.50% | -43.10 | AMGN | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | 27.2x | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | -2.24% | 3.25% | -5.49 | AMGN | /fcf-yield <GO> |
| Operating Margin | — | 24.70% | — | TIE | /operating-margins <GO> |
| Net Profit Margin | — | 21.00% | — | TIE | /net-margins <GO> |
| Revenue Growth (YoY) ACTIVE | 15.40% | 10.00% | +5.40 | RVMD | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 2.06% | -2.06 | AMGN | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 26.00 | 3.83 | +22.17 | RVMD | /balance-sheet <GO> |
| Piotroski F-Score Quality | 5/9 | 8/9 | -3.00 | AMGN | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 47.8 | 67.0 | -19.20 | AMGN | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 1.07 | 0.87 | +0.20 | RVMD | /macro-sensitivity <GO> |
| Forward P/E Multiple | 34.0x | 30.0x | +4.00 | AMGN | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $40.78B | $249.09B | -$208.30B | AMGN | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | RVMD REV | AMGN REV | RVMD GROSS % | AMGN GROSS % | RVMD FCF | AMGN FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $0 | $36.75B | — | 67.2% | -$913.7M | $8.10B |
| FY 2024 | $0 | $33.42B | — | 61.5% | -$567.7M | $10.39B |
| FY 2023 | $11.6M | $28.19B | — | — | -$351.1M | $7.20B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
RVMD // BETA 1.07
AMGN // BETA 0.87